Great to see a fresh discussion here!
Atria indeed published an updated strategy in mid-September, which Rauli commendably wrote about while I was on vacation. I find the new strategy interesting and distinctive in its industry due to, among other things, the following factors: a) The pursuit of international synergies, b) A new growth target, and c) Healthiness and the expansion of the raw material base. These themes will certainly not bring any quick wins in terms of earnings growth, nor is their long-term implementation guaranteed. However, the strategy is ambitious and long-term. HKFoods’ recently published strategy focused concisely on basic operations and improving profitability, compared to which Atria’s strategy is clearly different. In my view, the stock markets look at these companies with a fairly short time horizon, with results at the core. Selling a growth strategy and a longer perspective to investors therefore requires concrete successes in growth from Atria.
Let’s start with international synergies, which in my view clearly stands out from the industry mainstream. In the food industry, production has long been concentrated from regional units to national ones. The next logical step in efficiency and centralization thinking would be to serve an even larger area (e.g., the Nordic countries) through a single factory. However, in meat and ready-meal products, this type of export is relatively minor. If Atria could serve Swedish consumers from its Nurmo factories, this would offer volume growth and a higher scale, which could strengthen the company’s competitiveness. My understanding is that Atria is optimizing its new production units to also serve the Swedish market, for example, in terms of packaging and logistics.
I am not entirely without reservations about internationalization, as Atria, for example, has faced significant profitability challenges in its Swedish operations, which has also led to write-downs of intangible assets. If Atria could organically develop its operations and genuinely utilize synergies between countries, the company’s investment profile could strengthen compared to the present.
The new growth target of over 2 billion euros for 2030 is relatively close to our forecast (EUR 1.978 billion). It indicates a growth-oriented approach that the company states such a goal aloud. Perhaps at the CMD (November 21st) we will get more concrete details on how the target will be achieved, but I would assume that increasing international sales will have its own role in the target.
Expanding the raw material base indicates that the company is following long-term market trends, even though in the short term, plant-based proteins have not been particularly strong in growth (and competition is tough). Atria is, in my view, quite pragmatic regarding this theme, and I do not expect major moves in this area in the near future.